The Journal of Pulmonary & Respiratory Medicine, one of the most prestigious publications in the field of respiratory tract related diseases is publishing a feature about the interesting study on the effectiveness of telemedicine platforms such as Medtep in asthma control. The study shows how, by using the platform, patients reduce emergency visits and consequently treatments derived from asthmatic crisis.
Data are quite conclusive in this regard, since none of the participants had the need to go to the emergency room while using the platform, while in the six months prior to their participation 50% of them did had to be treated on an urgent basis.
On the other hand, none of the participants taking part in the study had to increase their treatment, and even 25% were able to reduce it, whereas 50% of them increased their treatment before entering the study.
In the following interview Dr. Pedro J. Tárraga, who is a member of the research team that conducted the study, tells us more about the success of the study and its impact through the publication in the Journal of Pulmonary & Respiratory Medicine.
Can you explain a little bit about the design, results and conclusions of the study? This is a pilot study on the results before and after the use of Medtep platform in patients diagnosed with asthma and treated by pneumologist. The study shows how the use of telemedicine by Medtep improves lung function and increases treatment adherence as well as therapeutic compliance.
How important it is that the results are being published by the Journal of Pulmonary & Respiratory Medicine? The publication in the Journal of Pulmonary & Respiratory Medicine will enhance dissemination of the study to a wider audience in the field of pneumology. Since it is an open access magazine, the feature could reach any specialist with an interest in learning about telemedicine in the asthma treatment.
What do you think will be the role of new technologies in optimizing asthma control? I believe new technologies are and will be extremely useful tools for both physicians and asthma patients, because anyone with a cell phone or tablet can inform their doctor about their current state and control how the treatment is evolving.
Will this study have a continuity? It definitely will. As I said, it was a pilot study, the main one is currently underway. It’s a study on Telemedicine Asthma Management approved by Albacete Committee of Inquiry and it already has the 50% of the participants taking part.
That’s good news! We’re looking forward to learn from the upcoming results. Thank you for your time Dr. Tárraga!
Digital Marketing & Social Media